中文名稱:Zevaquenabant | 英文名稱:Zevaquenabant |
CAS:1998760-00-1 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
產(chǎn)品類別: 抑制劑 | |
貨號: T39410 |
名稱 | Zevaquenabant |
描述 | Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD). |
體外活性 | Zevaquenabant can simultaneously inhibit CB1 receptors and iNOS in peripheral organs[1]. |
體內(nèi)活性 | Zevaquenabant (3 mg/kg; p.o.; for 28 days) improves renal morphological and functional parameters in diet-induced obese mice[1]. Animal Model: 6-week-old male C57Bl/6J mice (diet-induced obesity)[1]Dosage: 3 mg/kg Administration: P.o.; for 28 days Result: Improved kidney morphology and function in diet-induced obese mice. |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
關(guān)鍵字 | MRI 1867 | MRI1867 | MRI-1867 | Zevaquenabant |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 589.8595萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 中間體,天然產(chǎn)物,生物化工,化學試劑,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |